Beneficient Q2 operating loss widens on deeper investment, financial instruments losses
Overview
US alternative asset platform's fiscal Q2 revenue was negative, reflecting investment and financial instrument losses
Company posted a net loss attributable to common shareholders for the quarter
Operating expenses declined 6.9% yr/yr as management focused on cost reductions
Outlook
Company did not provide specific financial guidance for the current quarter or full year
Result Drivers
INVESTMENT AND FINANCIAL INSTRUMENT LOSSES - Co said negative revenue was mainly due to net investment losses and losses on financial instruments
COST REDUCTIONS - Operating expenses fell 6.9% yr/yr as management focused on efficiency and aligning costs with business activity
HIGHER CREDIT LOSSES AND ASSET SALES - Ben Liquidity segment's operating performance declined due to higher intersegment credit losses and asset sales
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | -$25.29 mln | ||
Q2 Loss Per Share | $1.49 |
Analyst Coverage
Wall Street's median 12-month price target for Beneficient is $9.00, about 1,331.5% above its November 13 closing price of $0.63
Reuters Recommended Reads
Nov 16 - Enanta Pharmaceuticals misses Q4 revenue estimates, posts wider net loss
Nov 16 - GoPro Q3 revenue falls 41% on hardware decline
Nov 16 - Greenlane raises going-concern doubts; Q3 net revenue falls 91% as legacy business winds down
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)